Abstract
Anti-Ro/SS-A is one specific type of antinuclear antibodies. They are in the majority of cases associated with primary Sjögren syndrome (SS) but also in Systemic Lupus Erythematosus (SLE), rheumatoid arthritis (RA), and in healthy people. During pregnancy, they are mainly associated to congenital heart block (CHB) and neonatal lupus (NL). The aim of this study was to compare the rate of maternal and fetal complications between a series of anti-Ro/SS-A positive pregnant women prospectively followed. Forty-two anti-Ro/SSA antibodies positive pregnant women that were referred to our hospital between 2011 and 2015. Data about pregnancy follow-up and outcomes were prospectively recorded from electronic databases. Data included demographic characteristics of the patients and their diseases (type, treatments, profile of anti-Ro/SSA, and antiphospholipid antibodies), pregnancy complications (CHB, preeclampsia, preterm delivery), ultrasound examinations and conditions, and mode of delivery. Maternal age was 35.22 ± 3.42 years and most of them were either SLE (n = 16, 40%) or Sjögren syndrome (n = 15, 37.5%). The rest of them were asymptomatic carriers (n = 8; 20%), and there was only one case of rheumatoid arthritis (n = 1; 2.5%). The incidence of anti-Ro52 and anti-Ro60 positive was n = 13, 82.4% and n = 16, 100%, respectively. Anti-La/SSB antibodies were present in n = 17, 48,6% of the patients. Half of the patients were taking hydroxycloroquine (n = 18, 45%). Seven pregnancies were complicated by fetal anti-Ro-related cardiac disease (17.9%) including four cases (57.1%) of second-degree heart block, two cases of third degree heart block (28.6%) and one case (14.3%) of intense and diffuse hyperechogenicity in atrioventricular valves without heart block. Gestational age at diagnosis of these conditions was 23.2 ± 3.5 weeks. One of the 18 patients having hydroxychloroquine (5.6%) compared with the six of them in women not having this medication (6/22, 27.3%) (p = 0.10). Concerning about Doppler evaluation, the Z score of umbilical pulsatility index (PI) was significantly higher in the SLE patients (p = 0.02). There were no cases of preeclampsia. Labor was induced in 21 cases (52.5%) and cesarean section rate was 45%. Gestational age at birth was 39 (37–40) weeks, and the general prematurity rate was 20% (n = 8). Birthweight was 2985 g (2425–3185 g) and 2850 (12.25–52.50) centiles for gestational age. The rate of small for gestational age (SGA) infants was 31.3% for SLE patients (5/16), 13.3% for Sjögren syndrome (2/15), and 12.5% for asymptomatic women (1/8). The rate of neonatal acidosis (pH < 7.20) was 20% (8/34) and it was higher in the SLE cases (6/15, 40%) when delivered after 38 weeks. The main pregnancy complication associated to anti-Ro/SS-A antibodies is CHB. The prevalence of CHB in patients taking hydroxychloriquine is lower without distinguishing between high or low risk patients. Preterm delivery occurs in anti-Ro/SS-A patients at the same rate as in the general population if no complications such as CHB or intrauterine growth restriction (IUGR) occur. The SGA rate also is higher probably because of SLE not because anti-Ro/SS-A antibodies. Finally, the finding of high umbilical artery PI will allow to predict fetus at risk of adverse pregnancy outcomes.
Highlights
•Anti-Ro/SS-A and anti-La/SS-B are clinically very relevant during pregnancy mainly because of their association to congenital heart block and neonatal lupus.
•In our cohort, the prevalence of congenital heart block detected in patients taking hydroxycloroquine is much lower than in patients not taking it without distinguishing between high and low risk patients.
•High umbilical artery pulsatility index in Doppler scans studies has been detected in our anti-Ro/SSA population (basely in SLE patients) demonstrated this measurement as a predictor of SGA and adverse pregnancy outcomes in general population such as cesarean section for fetal distress. The small for gestational age rate is higher probably because of SLE not because anti-Ro/SS-A
•Preterm delivery happens in anti-Ro/SS-A patients at the same rate as in the general population if no complications such as congenital heart block or intrauterine growth restriction occur.
Similar content being viewed by others
References
Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64:2319–27.
Bielsa Masdeu AM. Autoanticuerpos. Guía rápida. 2ª edición. Madrid: Ana María Bielsa Masdeu; 2010.
Hayashi N, Koshiba M, Nishimura K, et al. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol. 2008;18:153–60.
Guo YP, Wang CG, Liu X, Huang YQ, Guo DL, Jing XZ, Yuan CG, Yang S, Liu JM, Han MS, Li HX. The prevalence of antinuclear antibodies in the general population of China: a cross-sectional study. Curr Ther Res Clin Exp. 2014;76:116–9.
De Carolis S, Salvi S, Botta A, Garofalo S, Garufi C, Ferranzzani S, De Carolis MP. The impact of primary Sjögren’s syndrome on pregnancy outcome: our series and review of the literature. Autoimmune Rev. 2014;13:103–7.
Priori R, et al. Outcome of pregnancy in Italian patients with primary Sjögren syndrome. J Rhematol. 2013;40:1143–7.
Martínez-Sánchez N, Robles-Marhuenda A, Álvarez-Doforno R, Viejo A, Deirós-Bronte L, Bartha JL. The effect of a triple therapy on maternal anti-Ro/SS-A levels associated to fetal cardiac manifestations. Autoimmun Rev. 2015;14(5):423–8. doi:10.1016/j.autrev.2015.01.005.
Hull RG, Harris EN, Morgan SH, Hughes GR. Anti-Ro antibodies and abortions in women with SLE. Lancet. 1983;2:1138.
Watson RM, Braunstein BL, Watson AJ, Hochberg MC, Provost TT. Fetal wastage in women with anti-Ro(SSA) antibody. J Rheumatol. 1986;13:90–4.
Mavragani CP, Dafni UG, Txioufas AG, Moutsopoulos HM. Pregnancy outcome andi anti-Ro/SS-A in autoimmune disease: a retrospective cohort study. Br J Rheumatol. 1998;37:740–5.
Le Thi HD, Wechsler B, Piette JC, Bletry O, Godeau P. Pregnancy and its outcome in systemic lupus erythematosus. Q J Med. 1994;87:721–9.
Brucato A, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus. 2002;11:716–21.
Soh MC, Nelson-Piercy C. High-risk pregnancy and the rheumatologist. Rheumatology(Oxford). 2015;54(4):572–87. doi:10.1093/rheumatology/keu394.
Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126:76–82.
Alvarez D, Briassouli P, Clancy RM, et al. A novel role of endothelin-1 in linking toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem. 2011;286:3044–54.
Saxena A, Izmirly PM, Mendez B, Buyon JP, Friedman DM. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev. 2014;22(6):263–7.
Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640–7.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical markers at 30-34 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol. 2016;47(2):194–202. doi:10.1002/uog.14928.
Murthy K, Grobman WA, Lee TA, Holl JL. Trends in induction of labor at early-term gestation. Am J Obstet Gynecol. 2011;204:435.
Inducción del parto. Protocolo SEGO. 2013
Rayburn WF. Prostaglandin E2 gel for cervical ripening and induction of labor: a critical analysis. Am J Obstet Gynecol. 1989;160(3):529–34.
Cesárea. Protocol of SEGO (Obstetrics and Gynecology Spanish Society). 2015
Hussein SZ, Lennart THJ, Lindquist PG, Theander E. Pregnancy and fetal outcome in women with primary Sjögren syndrome compared with women in the general population: a nested case-control study. Rheum. 2011;50:1612–6.
Skog A, Lagnefeldt L, Conner P, Wahren-Herlenius M, Sonesson SE. Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block. Acta Obstet Gynecol Scand. 2016 Jan;95(1):98–105.
Amenaza de parto pretérmino. Protocolo SEGO. 2014
Chatelain P. Children born with intra-uterine growth retardation (IUGR) or small for gestational age (SGA): long term growth and metabolic consequences. Endocr Regul. 2000;33:33–6.
Julkunen H, Kaaja R, Kurki P, et al. Outcome in women with primary Sjogren’s syndrome. A retrospective case-control study. Clin Exp Rheumatol. 1995;13:65–71.
Diagnóstico prenatal. Protocol of SEGO (Obstetrics and Gynecology Spanish Society). 2009
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Rights and permissions
About this article
Cite this article
Martínez-Sánchez, N., Pérez-Pinto, S., Robles-Marhuenda, Á. et al. Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study. Immunol Res 65, 487–494 (2017). https://doi.org/10.1007/s12026-016-8888-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-016-8888-5